Armistice Capital

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, dedicated to developing therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031, a monoclonal antibody currently in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral inhibitor in Phase IIa trials for Crohn’s disease. Other notable candidates include PRV-3279, which has completed Phase 1b trials for lupus, and PRV-101, a vaccine targeting coxsackie virus B infections. Additionally, PRV-015, an anti-IL-15 monoclonal antibody, is being developed for celiac disease and is currently in Phase IIb trials. Provention Bio's innovative approach emphasizes early intervention in disease progression, positioning the company as a potential leader in a new biopharmaceutical category focused on the prevention of chronic autoimmune and inflammatory conditions.

Eyenovia, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing innovative microdose therapeutics using its proprietary piezo-print delivery technology known as the Optejet. This technology aims to enhance the delivery of ophthalmic medications by replacing traditional eye droppers, thereby improving safety, tolerability, and patient compliance. Eyenovia's pipeline includes several product candidates targeting prevalent eye diseases. The MicroLine program, currently in Phase III development, seeks to enhance near vision for patients with presbyopia. Additionally, MicroProst is in Phase III trials for chronic angle closure glaucoma and ocular hypertension, while MicroStat has completed Phase III trials for mydriasis. Other candidates include MicroTears for red eye relief and MicroPine for progressive myopia. Founded in 2014 and based in New York, Eyenovia aims to address unmet medical needs in ophthalmology by delivering next-generation therapies that improve the risk-benefit profile of existing treatments.

Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of imaging technologies for the diagnosis and treatment of cancer and other diseases. Its primary product, Cellvizio, is a confocal laser endomicroscopy platform that allows real-time, in vivo microscopic visualization of tissues at the cellular level. This technology aids physicians in accurately detecting early-stage pathologies and making informed therapeutic decisions. The company operates globally, with a significant presence in Europe, the United States, and various countries in Asia and Latin America. Mauna Kea Technologies generates revenue primarily from the sales of Cellvizio products and related accessories used in medical diagnostics and research.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for eye diseases. The company utilizes its proprietary platform technologies, including a non-invasive iontophoretic drug delivery system known as EyeGate II, which has been developed over a decade in collaboration with the Bascom Palmer Eye Institute at the University of Miami. Kiora Pharmaceuticals is focused on creating effective therapies for various ocular conditions, leveraging its unique delivery system to enhance the administration of medications for chronic diseases affecting the mid and posterior segments of the eye. Among its key products is the EyeGate Ocular Bandage Gel, designed for managing corneal epithelial wounds, and EGP-437, aimed at addressing inflammatory conditions such as ocular inflammation and pain in post-surgical cataract patients. The company has established license agreements with several academic institutions, underscoring its commitment to advancing eye care through innovative pharmaceutical solutions. Kiora Pharmaceuticals is headquartered in Waltham, Massachusetts, and was incorporated in 1998.

Medigus Ltd. is a medical device company based in Omer, Israel, that specializes in developing and marketing innovative minimally invasive endo-surgical tools and direct visualization technology. Founded in 1999, the company primarily focuses on the treatment of gastroesophageal reflux disease (GERD), a common chronic condition. Medigus has created an endoscopic system known as the SRS, which integrates a miniaturized video camera, surgical stapler, and ultrasonic alignment sights into a single device. This system allows gastroenterologists and surgeons to perform a partial anterior fundoplication endoluminally, significantly transforming GERD treatment by reducing reliance on traditional open or laparoscopic surgeries. In addition to its proprietary products, Medigus designs and manufactures endoscopy systems for partner companies, offering a range of technologies including small video cameras, video processors, and various types of endoscopes for diverse endoscopic procedures. The company operates globally across the United States, Europe, Asia, and other international markets.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.